Neurocrine Biosciences, Inc. (NBIX)

NASDAQ: NBIX · USD

$145

-0.60 (-0.4%)· Recorded snapshot

Market cap	14.8B
Revenue (ttm)	3.4B
Net income (ttm)	705.5M
EPS (ttm)	$6.82
Shares out	101.6M
P/E (trailing)	21.3x
P/E (forward)	12.8x
Volume	839,396
Beta	0.40

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 3.4B
Net income (ttm): 705.5M
EPS (ttm): $6.82
P/E (trailing): 21.3x
P/E (forward): 12.8x
Market cap: 14.8B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E12.8

P25 n/aP50 n/aP75 n/a

Trailing P/E21.3

P25 n/aP50 n/aP75 n/a

ROE22.1

P25 n/aP50 n/aP75 n/a

ROIC20.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All NBIX indicators

Market & fundamental data

Available fields

275

Groups with data

Currency

USD

Showing 275 of 275 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000914475
Company name	Neurocrine Biosciences, Inc.
Country	United States
Country code	US
CUSIP number	64125C109
Earnings date	2026-11-02
Earnings time	amc
Employees	2,500
Employees change	700
Employees growth	38.89%
Enterprise value	$14.9B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1992
Industry	Drug Manufacturers - Specialty & Generic
IPO date	1996-05-23
Is primary listing	Yes
Is SPAC	No
ISIN number	US64125C1099
Last 10-K release date	2026-02-11
Last earnings date	2026-07-30
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$14.8B
Market cap category	Large-Cap
Next earnings date	2026-11-02
Options	Yes
Price	$145.40
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	NBIX
U.S. state	California
Website	https://www.neurocrine.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	16.45x
Average P/E ratio (10Y)	150.61x
Average P/E ratio (3Y)	36.3x
Average P/E ratio (5Y)	94.43x
Earnings yield	4.69%
EV/Earnings	21.12x
EV/EBIT	17.21x
EV/EBITDA	16.32x
EV/FCF	17.12x
EV/Sales	4.42x
FCF / EV yield	5.84%
FCF yield	5.87%
Forward EV/Sales	3.43x
Forward P/E	12.76x
Forward P/S	3.41x
Graham number	74.70629
Graham upside	-48.8%
Industry forward P/E	13.86x
Industry P/E	173.47x
Lynch fair value	$96.25
Lynch upside	-34.03%
P/(FCF - SBC) ratio	23.32x
P/(OCF - SBC) ratio	22.35x
P/B ratio	4.02x
P/E ratio	21.31x
P/FCF ratio	17.04x
P/OCF ratio	16.51x
P/S ratio	4.4x
PEG ratio	0.32x
Price / tangible book value	15.34x
Price/EBITDA ratio	16.24x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	25.67%
EBITDA margin	27.07%
Effective tax rate	24.96%
FCF margin	25.8%
Gross margin	64.48%
Operating margin	25.67%
Pretax margin	27.87%
Profit margin	20.91%
Profit per employee	$282,200
Profitable quarters	13
Profitable years	8
Revenue per employee	$1.3M
ROA	11.7%
ROA (5Y)	8.57%
ROCE	19.31%
ROE	22.09%
ROE (5Y)	12.08%
ROIC	20.56%
ROIC (5Y)	20.75%
SBC / revenue	6.95%
Tax / revenue	6.96%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	101.21%
EPS growth (Q)	31.13%
EPS growth (QoQ)	-27.23%
EPS growth 3Y	57.74%
EPS growth 5Y	12.92%
EPS growth quarters	5
EPS growth years	4
FCF growth	64.63%
FCF growth (Q)	43.69%
FCF growth (QoQ)	-5.93%
FCF growth 3Y	45.81%
FCF growth 5Y	28.25%
Gross profit growth	37.17%
Gross profit growth (Q)	41.44%
Gross profit growth 3Y	24.47%
Gross profit growth 5Y	24.19%
Net income growth	102.56%
Net income growth (Q)	34.33%
Net income growth (QoQ)	-27.03%
Net income growth 3Y	58.73%
Net income growth 5Y	14.11%
Net income growth quarters	5
Net income growth years	4
OCF growth	58.31%
OCF growth (Q)	33.73%
OCF growth (QoQ)	-6.45%
OCF growth 3Y	44.74%
OCF growth 5Y	27.69%
Operating income growth	73.51%
Operating income growth (Q)	46.15%
Operating income growth 3Y	43.27%
Operating income growth 5Y	28.7%
Revenue growth	34.42%
Revenue growth (Q)	39.49%
Revenue growth (QoQ)	17.74%
Revenue growth 10Y	71.87%
Revenue growth 3Y	26.34%
Revenue growth 5Y	26.74%
Revenue growth quarters	20
Revenue growth years	9

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-27.7M
Depreciation and amortization	$47.3M
EBIT	$866M
EBITDA	$913.3M
EPS	$6.82
FCF per share	$8.56
Financing cash flow	$60.2M
Free cash flow	$870.4M
Free cash flow minus SBC	$635.9M
Gross profit	$2.2B
Income taxes	$234.7M
Investing cash flow	$-891.2M
Net cash flow	$66.9M
Net income	$705.5M
Operating cash flow minus SBC	$663.6M
Operating income	$866M
Revenue	$3.4B
Stock-based compensation	$234.5M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	6.57
Book value per share	$36.35
Debt / EBITDA	0.47
Debt / equity	0.12
Debt / FCF	0.53
Goodwill	$500.6M
Interest coverage	298.62
Long-term assets	$3.7B
Long-term liabilities	$791M
Net cash (debt)	$-71.8M
Net cash / market cap	-0.48%
Net debt / EBITDA	0.08
Net debt / equity	0.02
Net debt / FCF	0.08
Piotroski F-Score	6
Property, plant and equipment	$538.5M
Shareholders' equity	$3.7B
Tangible book value	$967M
Tangible book value per share	$9.52
Total assets	$5.4B
Total cash	$389.8M
Total debt	$461.6M
Total liabilities	$1.7B
WACC	6.27%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.73
Current assets	$1.6B
Current liabilities	$874.5M
Current ratio	1.87
Inventory turnover	14.88
Net working capital	$433M
Quick ratio	1.46
Working capital	$763M
Working capital turnover	3.43

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-0.78%
Dividend yield	0%
Shareholder yield	-0.78%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	224.7%
10Y return CAGR	12.5%
10Y total return	224.7%
150-day SMA	$152.25
15Y price change	2,070.15%
15Y return CAGR	22.77%
15Y total return	2,070.15%
1D price change	-0.41%
1M price change	5.06%
1M total return	5.06%
1W price change	2.89%
1W total return	2.89%
1Y price change	-2.38%
1Y return CAGR	-2.38%
1Y total return	-2.38%
20-day SMA	$141.47
200-day SMA	$147.25
20Y price change	1,109.65%
20Y return CAGR	13.28%
20Y total return	1,109.65%
3M price change	-17.58%
3M total return	-17.58%
3Y price change	37.08%
3Y return CAGR	11.08%
3Y total return	37.08%
50-day SMA	$146.95
50-day SMA vs 200-day SMA	50under200
52-week high	$186.12
52-week high date	2026-07-30
52-week low	$122.14
52-week low date	2026-02-12
5Y price change	43.59%
5Y return CAGR	7.51%
5Y total return	43.59%
6M price change	13.56%
6M total return	13.56%
All-time high	$186.12
All-time high date	2026-07-30
All-time low	$1.94
All-time low date	2009-11-30
Average true range (ATR)	$3.53
Average volume	1.3M
Beta (1Y)	0.56
Beta (2Y)	0.62
Beta (5Y)	0.4
Change from 52-week high	-21.88%
Change from 52-week low	19.05%
Change from all-time high	-21.88%
Change from all-time low	7,394.85%
Change from open	0.28%
Day's gap	-0.68%
Dollar volume	$122M
High price	$145.90
Low price	$144.36
Monthly RSI	53.26
Open price	$145.00
Position in 52-week range	67.53%
Premarket change	-1.14%
Premarket close	$146.00
Premarket price	$144.33
Premarket volume	5.5K
Previous close	$146.00
Price vs 150-day SMA	-4.5%
Price vs 20-day SMA	2.78%
Price vs 200-day SMA	-1.26%
Price vs 50-day SMA	-1.05%
Relative volume	0.66
RSI	54.25
Sharpe ratio	-0.02
Sharpe ratio (3Y)	0.35
Sharpe ratio (5Y)	0.25
Sortino ratio	0.13
Sortino ratio (3Y)	0.62
Sortino ratio (5Y)	0.5
Volume	839.4K
Weekly RSI	47.51
YTD price change	2.52%
YTD total return	2.52%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	100.4M
Float percentage	98.72%
Shares change (QoQ)	0.77%
Shares change (YoY)	0.78%
Shares held by insiders	1.2%
Shares held by institutions	102.11%
Shares outstanding	101.6M
Short % of float	6.42%
Short % of shares	6.34%
Short ratio	4.7 days

Deeper analysis on NBIX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this NBIX report

Is a complete NBIX research report available?

No complete published report is available for Neurocrine Biosciences, Inc. (NBIX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Neurocrine Biosciences, Inc. (NBIX)

Price

Financial snapshot

Fair-value bridge

Latest news · NBIX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NBIX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on NBIX

Frequently asked questions